Bridgefront Capital LLC bought a new position in Sana Biotechnology, Inc. (NASDAQ:SANA – Get Rating) during the 3rd quarter, HoldingsChannel reports. The fund bought 10,475 shares of the company’s stock, valued at approximately $63,000.
Several other hedge funds also recently made changes to their positions in SANA. Point72 Hong Kong Ltd purchased a new position in Sana Biotechnology during the 3rd quarter valued at $58,000. Quantamental Technologies LLC purchased a new position in Sana Biotechnology during the 3rd quarter valued at $70,000. Teacher Retirement System of Texas purchased a new position in Sana Biotechnology during the 2nd quarter valued at $81,000. XTX Topco Ltd purchased a new position in Sana Biotechnology during the 1st quarter valued at $86,000. Finally, Hsbc Holdings PLC purchased a new position in Sana Biotechnology during the 1st quarter valued at $90,000. 67.12% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Separately, Morgan Stanley reduced their price objective on shares of Sana Biotechnology from $15.00 to $13.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 24th.
Sana Biotechnology Trading Up 7.4 %
Insider Transactions at Sana Biotechnology
In other Sana Biotechnology news, Director Joshua H. Bilenker bought 20,000 shares of Sana Biotechnology stock in a transaction dated Friday, February 3rd. The shares were purchased at an average cost of $25.00 per share, with a total value of $500,000.00. Following the transaction, the director now directly owns 20,000 shares of the company’s stock, valued at $500,000. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 35.40% of the company’s stock.
About Sana Biotechnology
Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others.
- Get a free copy of the StockNews.com research report on Sana Biotechnology (SANA)
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
Want to see what other hedge funds are holding SANA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sana Biotechnology, Inc. (NASDAQ:SANA – Get Rating).
Receive News & Ratings for Sana Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sana Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.